Eltrombopag rebate agreement
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eltrombopag, ausgeschl. Anwendungsgebiet schwere aplastische Anämie in der Fachinformation, es sei denn, der Hersteller genießt hierfür Patenschutz, ATC B02BX05
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice explicitly says the contract documents must be submitted via the communication area of the DTVP portal and n...
The final contract-conclusion deadline is 03.08.2027, and monthly cut-offs apply for next-month starts; missing the cut...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2027
- Non-exclusive open-house rebate agreements for the medicinal product Eltrombopag (ATC B02BX05).
- Exclusion of the severe aplastic anemia indication in the product information, unless the manufacturer has patent protection for that indication.
Show full summary
Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Eltrombopag (ATC B02BX05), excluding the severe aplastic anemia indication unless the manufacturer has patent protection for that indication. The contracting buyer is AOK Bayern. This is explicitly described as a non-competitive open-house model with no selection of one or more bidders; any pharmaceutical company meeting the stated suitability requirement may join on identical, non-negotiable terms. Contracting is possible until 03.08.2027, with monthly start dates depending on when complete documents are received. Procurement documents are available via DTVP, but only the notice text was analyzed, not the full document set.
Risks
The notice explicitly says the contract documents must be submitted via the communication area of the DTVP portal and n...
The final contract-conclusion deadline is 03.08.2027, and monthly cut-offs apply for next-month starts; missing the cut...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Eltrombopag rebate agreement
Open-house rebate agreement for Eltrombopag, excluding the severe aplastic anemia indication in the product information unless the manufacturer has patent protection for that indication. Scope is supplies of pharmaceutical products under a non-exclusive, identical, non-negotiable rebate contract. The lot information comes from structured data and notice text.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Eltrombopag, ausgeschl. Anwendungsgebiet schwere aplastische Anämie in der Fachinformation, es sei denn, der Hersteller genießt hierfür Patenschutz, ATC B02BX05
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 533121-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice explicitly says the contract documents must be submitted via the communication area of the DTVP portal and n...
The final contract-conclusion deadline is 03.08.2027, and monthly cut-offs apply for next-month starts; missing the cut...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications